The Challenges and Opportunities in Clinical Trial Diversity Mistrust in the healthcare system is a significant barrier to recruitment

Lisa Bailey

DOI: https://doi.org/10.1016/j.drudis.2024.104210

IF: 8.369

2024-10-21

Drug Discovery Today

Abstract:Drug Discov Today . 2024 Oct 17:104210. doi: 10.1016/j.drudis.2024.104210. Online ahead of print. NO

pharmacology & pharmacy

What problem does this paper attempt to address?

Enhancing Diversity and Inclusion in Clinical Trials

Amy Corneli,Emily Hanlen‐Rosado,Kevin McKenna,Richardae Araojo,Dawn Corbett,Kaveeta Vasisht,Bernadette Siddiqi,Tesheia Johnson,Luther T. Clark,Sara B. Calvert

DOI: https://doi.org/10.1002/cpt.2819

2023-01-11

Clinical Pharmacology & Therapeutics

Abstract:Women and people from most racial and ethnic groups in the United States have historically been under-represented in clinical trials of investigational medical products. Inadequate representation of these groups may lead to an incomplete understanding of the safety and efficacy of new drugs, devices, biologics, and vaccines, and limit the generalizability of trial findings. As a result, new medical products may not be beneficial to all people who need them, and existing inequities in outcomes among various population groups may remain unchanged or worsen, or new disparities may arise. Although much work has focused on study-level strategies, research organizations must make systemic changes to how clinical trials are envisioned and implemented to achieve sustainable support for diversity and inclusion in clinical trials. The Clinical Trials Transformation Initiative (CTTI) conducted interviews with leaders at institutions that conduct clinical trials to explore perspectives on organizational-level practices that promote diversity and inclusion in clinical trials. Leaders described motivations, such as an ethical and moral imperative; organizational practices, such as staff investment and resource allocation; perceived return on investments, such as better science; and deterrents, such as cost and time. The CTTI also convened an expert meeting to discuss the interview findings and provide guidance. We present the interview findings and expert guidance in a framework that describes four key areas-commitment, partnerships, accountability, and resources-on sustaining organizational-level approaches for improving diversity and inclusion in clinical trials, with the ultimate goal of advancing health equity. Institutions who conduct and support clinical trials should implement organizational-level approaches to improve equitable access and diverse patient participation in clinical trials.

pharmacology & pharmacy
Clinical Trial Access in Diverse Populations

Tareefe Montaque,John Stewart

DOI: https://doi.org/10.1002/jso.28010

2024-11-28

Journal of Surgical Oncology

Abstract:Despite the disproportionate impact of cancer on minority groups, their participation in oncologic clinical trials remains low. Contributing factors include mistrust of the medical establishment, structural barriers, and implicit bias. Strategies to improve access and representation include pragmatic trial designs, patient navigation programs, financial support, and increasing diversity among medical professionals. Addressing these issues is crucial for ensuring equitable healthcare delivery and improving outcomes for underrepresented populations in clinical research.

oncology,surgery
Challenges and strategies for recruitment of minorities to clinical research and trials

Susan P. Fisher-Hoch,Jennifer E. Below,Kari E. North,Joseph B. McCormick

DOI: https://doi.org/10.1017/cts.2023.559

2023-06-14

Journal of Clinical and Translational Science

Abstract://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS2059866123005599/resource/name/firstPage-S2059866123005599a.jpg
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives

Robin Chatters,Munyaradzi Dimairo,Cindy Cooper,Shamila Ditta,Jonathan Woodward,Katie Biggs,Della Ogunleye,Fiona Thistlethwaite,Christina Yap,Alexander Rothman,Chatters,R.,Dimairo,M.,Cooper,C.,Ditta,S.,Woodward,J.,Biggs,K.,Ogunleye,D.,Thistlethwaite,F.,Yap,C.,Rothman,A.

DOI: https://doi.org/10.1136/bmjopen-2023-075547

IF: 3.006

2024-03-20

BMJ Open

Abstract:Objectives To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. Design Qualitative interviews analysed using thematic analysis. Setting and participants Five professionals (clinical researchers and methodologists) and three patient and public representatives (those with experience of early-phase clinical trials and/or those from ethnic minority backgrounds) were interviewed between June and August 2022. Participants were identified via their institutional web page, existing contacts or social media (eg, X, formerly known as Twitter). Results Professionals viewed that diversity is not currently considered in all early-phase clinical trials but felt that it should always be taken into account. Such trials are primarily undertaken at a small number of centres, thus limiting the populations they can access. Referrals from clinicians based in the community may increase diversity; however, those referred are often not from underserved groups. Referrals may be hindered by the extra resources required to approach and recruit underserved groups and participants often having to undertake 'self-driven' referrals. Patient and public representatives stated that diversity is important in research staff and that potential participants should be informed of the need for diversity. Those from underserved groups may require clarification regarding the potential harms of a treatment, even if these are unknown. Education may improve awareness and perception of early-phase clinical trials. We provide 14 recommendations to improve diversity in early-phase clinical trials. Conclusions Diversity should be considered in all early-phase trials. Consideration is required regarding the extent of diversity and how it is addressed. The increased resources needed to recruit those from underserved groups may warrant funders to increase the funds to support the recruitment of such participants. The potential harms and societal benefits of the research should be presented to potential participants in a balanced but accurate way to increase transparency.

medicine, general & internal
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Michelle D Kelsey,Bray Patrick-Lake,Raolat Abdulai,Uli C Broedl,Adam Brown,Elizabeth Cohn,Lesley H Curtis,Chris Komelasky,Michael Mbagwu,George A Mensah,Robert J Mentz,Amesika Nyaku,Stephanie O Omokaro,Judy Sewards,Kendal Whitlock,Xinzhi Zhang,Gerald S Bloomfield

DOI: https://doi.org/10.1016/j.cct.2022.106740

Abstract:Background: Improving diversity in clinical trials is essential in order to produce generalizable results. Although the importance of representation has become increasingly recognized, identifying strategies to approach this work remains elusive. This article reviews the proceedings of a multi-stakeholder conference about the current state of diversity in clinical trials and outlines actionable steps for improvement. Methods: Conference attendees included representatives from the United States Food and Drug Administration (FDA), National Institutes of Health (NIH), practicing clinical investigators, pharmaceutical and device companies, community-based organizations, data analytics companies, and patient advocacy groups. At this virtual event, attendees were asked to consider key questions around best practices for engagement of underrepresented populations. Results: Community engagement is an integral part of recruitment and retention of underrepresented groups. Decentralization of sites and use of digital tools can enhance the accessibility of clinical research. Finally, improving representation among investigators and clinical research staff may translate to diverse clinical trial participants. Conclusion: Improving diversity in clinical trials is an ethical and scientific imperative, which requires a multifaceted approach.
Why diversity is needed at every level of clinical trials, from participants to leaders

Khadijah Breathett

DOI: https://doi.org/10.1038/s41591-024-02914-x

IF: 82.9

2024-04-12

Nature Medicine

Abstract:Diversity in clinical trials must be accompanied by justice and equity, including benefits for underrepresented participants, in order to boost population health.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel

Bhavana Pothuri,Premal Thaker,Adrienne Moore,Rosa Espinosa,Kara Medina,Deborah Collyar,Kathleen Lutz,Mihaela C Munteanu,Brian Slomovitz

DOI: https://doi.org/10.1136/ijgc-2024-005751

2024-09-13

Abstract:Lack of patient diversity in clinical trial enrollment remains an obstacle to achieving equitable healthcare outcomes. Under-representation has resulted in non-generalizable clinical knowledge, inequitable access to treatment, and health disparities among minority and disadvantaged groups. A multidisciplinary panel was convened to consider the challenges of diverse patient accrual and provide actionable solutions to improve representation in clinical trials. The panel was comprised of participants with knowledge in gynecologic oncology and included physician, advanced practice nurse, patient navigator, patient advocate, and pharmaceutical industry representation. Focus was given to recruitment barriers for Asian and Hispanic patients. The panel identified several areas of concern, including explicit and implicit biases for the physician and care teams, language and cultural nuances, inadequate inclusion of family in the decision-making process, and under-representation of women in clinical trials. The panel also identified the important role patient navigators, nurses, and advanced practice providers have in patient recruitment from under-represented populations. The role of study sponsors, and global and regional initiatives, to address historic disparities in clinical trial recruitment were also considered critical. The actionable solutions proposed should enable study sponsors and clinical trial sites to achieve greater diversity in enrollment globally.
On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.

Kimberley T Lee,Rebecca M. Blackwell,Melinda Leigh Maconi,Carley Geiss,Susan Thomas Vadaparampil,Brian D. Gonzalez,Heather S.L. Jim,Clement K Gwede,Hatem Hussein Soliman

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13674

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:e13674 Background: Racial and ethnic diversity in cancer clinical trials remains low. In this formative work, we sought to better characterize patient attitudes towards clinical trial participation. The goal is to build a framework that can be leveraged to develop an intervention to increase enrollment of participants from racial and ethnic minority groups in clinical trials. Methods: Semi-structured interviews were conducted with 10 Black and 10 Hispanic breast cancer survivors receiving care at a comprehensive cancer center in the South. Interviews were recorded, transcribed verbatim, and coded using thematic analysis. Results: Patient attitudes to clinical trials were generally positive. Many felt that trials were beneficial and a necessary part of advancing medical science. However, many expressed hesitations with regards to trial participation due to safety and efficacy concerns and distrust regarding motivation of healthcare system. Facilitators of positive attitudes towards clinical trials included positive social circles including family and community, as well as altruism regarding supporting racial and ethnic diversity in clinical trials. Conclusions: Collectively, these findings underscore the importance of implementing strategies to foster diversity in the biomedical research community, community outreach, and lay education, to improve trust in the system and therefore attitudes towards clinical trial participation in minority populations. [Table: see text]

oncology
A successful clinical trial ecosystem offers equal opportunities for all citizens

Tarec Christoffer El‐Galaly,Anne Stidsholt Roug,Daniel Tuyet Kristensen

DOI: https://doi.org/10.1111/bjh.19927

2024-11-30

British Journal of Haematology

Abstract:An inclusive clinical trial ecosystem is essential to obtain scientific results that can be generalized to a broad patient population. When possible, all efforts should be made to remove geographic, demographic, cultural and ethnic barriers for enrolment in clinical trials. However, to do this effectively, we need more knowledge about factors influencing clinical trial participation and practical frameworks to enhance diversity in clinical trials. Commentary on: Jones et al. Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19907.

hematology
How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.

Tariqa Ackbarali,Ricki Fairley,Susan Thomas Vadaparampil,Aaron Elliott Lisberg,Raymond U. Osarogiagbon,Monique Gary

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.6510

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:6510 Background: Some of the greatest disparities in cancer care are related to clinical trial access for our patients. To address the racial/ethnic disparities in breast and lung cancer clinical trials, a tethered educational initiative was designed to empower patients, assess current clinician perceptions/practices, and improve awareness of real-world perspectives of clinical trials. Methods: Two, one-hour online, interactive, video-based programs were designed for patients, caregivers, and providers. This patient/caregiver program was hosted on CancerCoachLive and MedLive in November, 2022, while the provider program was hosted on ClinicalSeriesLive in December, 2022 and will remain on-demand until December 2023. This initiative was conducted in collaboration with TOUCH, the Black Breast Cancer Alliance, BlackDoctors.org, Moffitt Cancer Center, CancerCare, and the Lung Cancer Research Foundation. Herein, we report on an analysis from patients and providers regarding clinical trial diversity, behavioral impact, and qualitative insights. Results: As of data cut-off (02/10/23), 1,425 participants have engaged across both educational programs. Of participating patients, 46% were non-White (non-Hispanic), 36% were in remission, 36% were not on active treatment, and 29% were newly diagnosed. Following the program 81% were motivated to take one or more actions over the next two months: the most common actions being to research clinical trials (38%) or discuss clinical trials with a clinician (19%). Post-activity, 79% were confident to very confident discussing clinical trials with a clinician. Critical data related to clinician preferences was assessed and demonstrated a 23% increase in confidence from pre- to post-activity in improving diversity in clinical trial participation with preferences observed in both breast and lung cancers to offer clinical trials for newly diagnosed and second recurrence settings. Of those who are being offered clinical trials in the community setting, there was a higher likelihood for patients to be offered a clinical trial if their subtype was HER2+ breast cancer subtype or NSCLC with an actionable mutation. Data collection continues as this initiative is ongoing. Qualitative data including clinician write-in examples of behavioral impact and patient perspectives from the interviews will be shared. Conclusions: The outcomes discussed herein reveal a willingness from patients/caregivers to engage in clinical trial discussions and participate in clinical trials, if eligible. These educational programs positively impacted clinician motivation to address barriers to enrollment and clinical trial eligibility with their patients. Real-world accounts of patient experiences provide different perspectives that can help improve approaches to improve clinical trial diversity.

oncology
Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies

Jennifer Miller,William Pelletiers,Sakinah Suttiratana,Michael Ofosu Mensah,Jason Schwartz,Reshma Ramachandran,Cary Gross,Joseph S Ross

DOI: https://doi.org/10.1136/bmjmed-2024-000920

2024-07-10

Abstract:Objective: To develop a reference standard based on US Food and Drug Administration and stakeholder guidance for pharmaceutical companies' policies on diversity in clinical trials and to assess these policies. Design: Development of a reference standard and structured audit for clinical trial diversity policies. Setting: 50 pharmaceutical companies selected from the top 500 by their market capitalizations in 2021 (the 25 largest companies and 25 non-large companies, randomly selected from the remaining 475 companies). Population: Data from pharmaceutical company websites and annual reports. Policy guidance from the Pharmaceutical Research and Manufacturers of America, International Federation of Pharmaceutical Manufacturers and Associations, Biotechnology Industry Organization, International Committee of Medical Journal Editors, the US Food and Drug Administration, European Medicines Agency, and World Health Organization, up to 15 May 2023. Main outcome measures: Multicomponent measure based on distinct themes derived from FDA and stakeholder guidance. Results: Reviewing FDA and stakeholder guidance identified 14 distinct themes recommended for improving diversity in clinical trials, which were built into a reference standard: (1) enrollment targets that reflect the prevalence of targeted conditions in populations, (2) broad eligibility criteria for trials, (3) diversity in the workforce, (4) identification and remedy of barriers to trial recruitment and retention, (5) incorporation of patient input into trial design, (6) health literacy, (7) multidimensional approaches to diversity, (8) sites with diverse providers and patient populations, (9) data collection after product approval, (10) diverse enrollment in every country where trials are conducted, (11) diverse enrollment should be a focus for all phases of clinical trials, not just later stage or pivotal trials, (12) varied trial design, (13) expanded access, and (14) public reporting of the personal characteristics of participants in trials. Applying this reference standard, 48% (24/50) of companies had no public policy on diversity in clinical trials; among those with policies, content varied widely. Large companies were more likely to have a public policy than non-large companies (21/25, 84% v 5/25, 20%, P<0.001). Large companies most frequently committed to using epidemiological based trial enrollment targets representing the prevalence of indicated conditions in various populations (n=15, 71%), dealing with barriers to trial recruitment (n=15, 71%), and improving patient awareness of trial opportunities (n=14, 67%). The location of the company was not associated with having a public diversity policy (P=0.17). The average company policy had five of the 14 commitments (36%, range 0-8) recommended in FDA and stakeholder guidance. Conclusions: The findings of the study showed that many pharmaceutical companies did not have public policies on diversity in clinical trials, although policies were more common in large than non-large companies. Policies that were publicly available varied widely and lacked important commitments recommended by stakeholder guidance. The results of the study suggest that corporate policies can be better leveraged to promote representation and fair inclusion in research, and implementation of FDA and stakeholder guidance.
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

L. Vidal,Z. Dlamini,S. Qian,P. Rishi,M. Karmo,N. Joglekar,S. Abedin,R.A. Previs,C. Orbegoso,C. Joshi,H.A. Azim,H. Karkaria,M. Harris,R. Mehrotra,M. Berraondo,G. Werutsky,S. Gupta,N. Niikura,I. Chico,K.S. Saini

DOI: https://doi.org/10.1016/j.esmoop.2024.103373

IF: 6.883

2024-05-10

ESMO Open

Abstract:Some races, ethnicities, geographies, genders, ages, abilities, and economic classes are underrepresented in cancer trials. There is strong scientific and ethical rationale for inclusiveness, equity, and diversity in cancer trial populations. Stakeholders including regulators, sponsors, CROs, patient groups, and oncology journals are advocating for such diversity. Cancer trials should answer scientific questions of relevance to the diverse participating subgroups. The burden of cancer exerts a disproportionate impact across different regions and population subsets. Disease-specific attributes, coupled with genetic and socioeconomic factors, significantly influence cancer treatment outcomes. Precision oncology promises the development of safe and effective options for specific ethnic phenotypes and clinicodemographic profiles. Currently, clinical trials are concentrated in resource-rich geographies with younger, healthier, white, educated, and empowered populations. Vulnerable and marginalized people are often deprived of opportunities to participate in clinical trials. Despite consistent endeavors by regulators, industry, and other stakeholders, factors including diversity in trial regulations and patient and provider-related cultural, logistic, and operational barriers limit the inclusiveness of clinical trials. Understanding and addressing these constraints by collaborative actions involving regulatory initiatives, industry, patient advocacy groups, community engagement in a culturally sensitive manner, and designing and promoting decentralized clinical trials are vital to establishing a clinical research ecosystem that promotes equity in the representation of population subgroups.

oncology
Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: A systematic review

Amy Kasahara,Jennifer Mitchell,Joshua Yang,Raphael E. Cuomo,Tiana J. McMann,Tim K. Mackey

DOI: https://doi.org/10.1177/20552076241242390

2024-01-01

Digital Health

Abstract:Background Many clinical trials fail because of poor recruitment and enrollment which can directly impact the success of biomedical and clinical research outcomes. Options to leverage digital technology for improving clinical trial management are expansive, with potential benefits for improving access to clinical trials, encouraging trial diversity and inclusion, and potential cost-savings through enhanced efficiency. Objectives This systematic review has two key aims: (1) identify and describe the digital technologies applied in clinical trial recruitment and enrollment and (2) evaluate evidence of these technologies addressing the recruitment and enrollment of racial and ethnic minority groups. Methods We conducted a cross-disciplinary review of articles from PubMed, IEEE Xplore, and ACM Digital Library, published in English between January 2012 and July 2022, using MeSH terms and keywords for digital health, clinical trials, and recruitment and enrollment. Articles unrelated to technology in the recruitment/enrollment process or those discussing recruitment/enrollment without technology aspects were excluded. Results The review returned 614 results, with 21 articles (four reviews and 17 original research articles) deemed suitable for inclusion after screening and full-text review. To address the first objective, various digital technologies were identified and characterized, which included articles with more than one technology subcategory including (a) multimedia presentations (19%, n = 4); (b) mobile applications (14%, n = 3); (c) social media platforms (29%, n = 6); (d) machine learning and computer algorithms (19%, n = 4); (e) e-consenting (24%, n = 5); (f) blockchain (5%, n = 1); (g) web-based programs (24%, n = 5); and (h) virtual messaging (24%, n = 5). Additionally, subthemes, including specific diseases or conditions addressed, privacy and regulatory concerns, cost/benefit analyses, and ethnic and minority recruitment considerations, were identified and discussed. Limited research was found to support a particular technology's effectiveness in racial and ethnic minority recruitment and enrollment. Conclusion Results from this review illustrate that several types of technology are currently being explored and utilized in clinical trial recruitment and enrollment stages. However, evidence supporting the use of digital technologies is varied and requires further research and evaluation to identify the most valuable opportunities for encouraging diversity in clinical trial recruitment and enrollment practices.

public, environmental & occupational health,health care sciences & services,medical informatics,health policy & services
Regulatory landscape with U.S. patient requirements and Clinical Trial Diversity expectations

Elizabeth George,Alicia Baker McDowell,Melissa Vozza,Talley Mitchell,Ben Quartley,Cassandra S Kennedy,Bill Hanlon

DOI: https://doi.org/10.1016/j.conctc.2024.101331

2024-07-06

Abstract:The Food and Drug Administration (FDA) has an expectation that products filed for marketing authorization have to include data that are representative of the US patient population. Any foreign clinical data that is submitted has to represent an ethnically diverse population that is generated utilizing qualified Principal Investigators (PIs) and conducted according to Good Clinical Practices (GCP) requirements outlined in 21 CFR 312.120, Foreign clinical studies not conducted under an IND. With the recent passing of the Omnibus Legislation, FDA now also has the authority to require Diversity Plans for all Phase 3 clinical trials of new drugs or "as appropriate, another pivotal study of a new drug." The FDA has released a guidance document, "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials" (April 2022), for the industry with expectations to update the document in 2023 now that legislation is passed. This whitepaper discusses the FDA guidance and expectations of sponsors with regards to foreign clinical data and the intersection with enrolling ethnically diverse populations in clinical studies.
Abstract A087: "Trust is built in teaspoons and it's lost in buckets": Clinical trial recruitment of Black individuals with lung cancer

Sarah C. Stallings,Andrew Ciupek,Kemberlee Bonnet,David G. Schlundt,William Opoku-Agyeman,Jennifer C. King,Nagla Abdel Karim,Christine M. Lovly,Melinda C. Aldrich,Soumya J. Niranjan

DOI: https://doi.org/10.1158/1538-7755.disp23-a087

2023-12-02

Cancer Epidemiology Biomarkers & Prevention

Abstract:Black individuals with cancer are underrepresented in clinical trials, which has implications for understanding how therapies work in all patient populations. To achieve representative trial enrollment of Black persons with cancer, it is critical to understand the barriers to participation in this population. Due to stigma from perceptions around lung cancer's association with smoking behavior, the barriers in this population may be complex compared to other cancer types. This study utilized a mixed-methods approach to decipher provider-reported barriers and facilitators to trial participation specificly among Black lung cancer patients. Providers across three institutions in the Southeastern US were interviewed using a semi-structured interview guide. Recorded and transcribed interviews and free text responses were analyzed by an independent coder using NVivo. Themes were generated using a content analysis approach. Data triangulation was achieved via anonymous surveys which were administered via REDCap. Across three institutions, 38 total, eligible, providers were recruited, having an average of 8.8 years of clinical practice. Nearly half (n=17, 44.7%) self-identified as Medical Oncologists. In the survey data barriers to clinical trial participation noted by the providers as expressed most often by black people with lung cancer were "being worried about the 'experimental nature' of clinical trial treatments" and "not wanting to be a 'research subject'. The barrier least reported was "being worried about having to see another provider for the trial". Provider perception of the reason that most contributes to lower trial participation of black people with lung cancer was "lack of trust in the medical system" (n = 18). Interestingly, when asked about perceptions of operational or system level barriers that contributed to lower clinical trial participation among lung cancer patients that identify as Black, providers reported "lack of appropriate trials" and "low numbers of Black patients seen". Three overarching themes emerged from the qualitative interview data (i) Barriers to recruitment were seen at individual, institutional and structural levels. (ii) Facilitators were seen mostly at the individual provider level and were predominantly based on engendering trust between the patient and provider. (iii) Solutions were largely related to increasing awareness around clinical trials using community engagement. Providers in our study reported patient centric barriers to recruitment such as lack of trust and systems barriers such as not having appropriate trials available locally. Providers reported facilitators to increasing recruitment of Black individuals with lung cancer via community outreach and building provider/patient trust. Institutions should develop culturally appropriate outreach programs to enroll racially diverse patients to lung cancer trials and trialists should explore strategies to increase trial offering and access in key communities. Citation Format: Sarah C. Stallings, Andrew Ciupek, Kemberlee Bonnet, David G. Schlundt, William Opoku-Agyeman, Jennifer C. King, Nagla Abdel Karim, Christine M. Lovly, Melinda C. Aldrich, Soumya J. Niranjan. "Trust is built in teaspoons and it's lost in buckets": Clinical trial recruitment of Black individuals with lung cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl) nr A087.

oncology,public, environmental & occupational health
Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators.

Ana I. Velazquez Manana,Evelin Trejo,Sorbarikor Piawah,Celia Kaplan

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1619

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:1619 Background: Multiple barriers limit the enrollment of diverse populations in oncology clinical trials (CTs). A review of our institutional CTs recruitment dashboard identified underrepresentation of Black and Latinx adults among thoracic and gastrointestinal (GI) oncology CTs participants compared to demographics of our catchment area and patient population. We conducted a mixed-methods study to identify barriers and potential solutions to the enrollment of diverse populations in oncology CTs in our institution. Methods: We conducted a mixed methods study enrolling clinical investigators and clinical research coordinators’ (CRCs) at an NCI-designated CCC in Northern California. Data from CRCs is presented. All CRCs supporting CTs in the thoracic and GI medical oncology were invited to participate in qualitative, one-on-one, semi-structured interviews. Participants completed 60-90 minutes interview and a short survey. Data were analyzed using a thematic inductive approach. Results: Of 14 CRCs, the majority were female (78.6%), with primary focus on thoracic (50.0%) and GI (35.7%) oncology CTs. 64.3% of CRCs reported >80% of their work was dedicated to coordinating and managing therapeutic cancer CTs. In survey responses CRCs identified inability to take time away from work/family (64.3%), inadequate insurance coverage (42.9%), lack of transportation (35.7%), and language barriers (35.7%) as major barriers to enrollment of diverse patients in CTs. In qualitative interviews CRCs expressed the need of culturally and language appropriate materials for CT recruitment, establishing a sense of connection between clinical research staff/PI and patients, accommodating socioeconomic concerns, and resources to respond to potential participants’ mistrust of medical research. Main obstacles faced by CRCs during patient enrollment in CTs included lack of time, low patient awareness, resistance from colleagues, lack of multilingual staff, and inadequate logistical support. CRCs identified in-person interpretation as beneficial and identified a strong rapport between the clinical provider and the potential participant as the most important component to boost recruitment of minorities. Lastly, CRCs highlighted that institutional efforts are needed to increase CT participation among all populations. Conclusions: Lack of representation of diverse populations in CTs remains a complex challenge. Our study of CRCs’ perceptions highlights access to in-person translators, culturally and language concordant materials, education resources, and increased rapport as key areas for intervention to facilitate patient enrollment of diverse populations. Analysis into practice-specific patterns within our cancer centers can help identify areas for interventions to support the recruitment and enrollment of diverse populations in oncology CTs.

oncology
"First, Trust Needs to Develop": Hematologists' Perspectives on Factors Influencing Black Persons' Participation in Clinical Trials

Shakira J. Grant,Milenka Jean-Baptiste,Jiona A. Mills,Paul Mihas

DOI: https://doi.org/10.1007/s40615-024-02205-8

2024-10-19

Journal of Racial and Ethnic Health Disparities

Abstract:Cancer clinical trials are crucial for treatment standards and innovation but lack racial-ethnic diversity. Understanding physician perspectives on recruiting participants is critical due to their role in decision-making about trial candidacy and enrollment.

public, environmental & occupational health
Critical decisions: A mixed-methods study of decision-making among diverse gynecologic cancer patients considering therapeutic clinical trial enrollment

Stephanie Margrit Rieder,Ellen Burgess,Teresa Rutledge,Andrew Sussman,Tawny Boyce,Vernon Shane Pankratz,Miria Kano

DOI: https://doi.org/10.1016/j.ygyno.2024.01.031

IF: 5.304

2024-05-01

Gynecologic Oncology

Abstract:OBJECTIVE: Participation in therapeutic clinical trials does not reflect the diversity of gynecologic cancer patients, limiting access to novel therapeutics and generalizability of results. Reasons for inequities in participation among historically underrepresented populations remain undertheorized, as studies have shown equal willingness to participate among groups. We sought to apply a precarity framework to conceptualize the factors that impact patients' desire to enroll, to improve equity in gynecologic oncology clinical trial participation.METHODS: Gynecologic cancer patients at a single tertiary care facility in the Southwestern United States who discussed participation in therapeutic clinical trial with their oncology provider from 2020 to 2021 were identified. Enrolled participants completed surveys and qualitative interviews regarding treatment experiences and decision-making. Oncology providers completed parallel surveys at the time of their patient's enrollment. Descriptive statistics and thematic coding were used to analyze data.RESULTS: 30 patients were enrolled and participated in surveys and interviews. No differences were found in quantitative data assessing shared decision-making and patient-centered communication between those who enrolled and those who did not. Qualitative data demonstrated that patients who declined trial enrollment expressed concerns regarding uncertainty and loss of control, independence in decision-making, and significant resource challenges and financial toxicity of cancer treatment.CONCLUSIONS: We identified a constellation of factors that contribute to desire to enroll in clinical trials, that we describe using the framework of precarity. Through identification of precarious patients and mitigation of burdens, we anticipate improved enrollment and retention in therapeutic clinical trials among diverse gynecologic oncology patients.

oncology,obstetrics & gynecology
Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone

Vindell Washington,Joseph B. Franklin,Erich S. Huang,Jessica L. Mega,Amy P. Abernethy

DOI: https://doi.org/10.1002/cpt.2804

2022-12-15

Clinical Pharmacology & Therapeutics

Abstract:Healthcare disparities are a persistent societal problem. One of the contributing factors to this status quo is the lack of diversity and representativeness of research efforts, which result in nongeneralizable evidence that, in turn, provides suboptimal means to enable the best possible outcomes at the individual level. There are several strategies that research teams can adopt to improve the diversity, equity, and inclusion (DEI) of their efforts; these strategies span the totality of the research path, from initial design to the shepherding of clinical data through a potential regulatory process. These strategies include more intentionality and DEI-based goal-setting, more diverse research and leadership teams, better community engagement to set study goals and approaches, better tailored outreach interventions, decentralization of study procedures and incorporation of innovative technology for more flexible data collection, and self-surveillance to identify and prevent biases. Within their remit of overlooking research efforts, regulatory authorities, as stakeholders, also have the potential for a positive effect on the DEI of emerging clinical evidence. All these are implementable tools and mechanisms that can make study participation more approachable to diverse communities, and ultimately generate evidence that is more generalizable and a conduit for better outcomes. The research community has an imperative to make DEI principles key foundational aspects in study conduct in order to pursue better personalized medicine for diverse patient populations.

pharmacology & pharmacy
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies

Nadia Islam,Laura Budvytyte,Nandita Khera,Talal Hilal

DOI: https://doi.org/10.1007/s11899-024-00747-6

2024-12-06

Current Hematologic Malignancy Reports

Abstract:Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across different populations. This review aims to examine the persistent disparities noted in clinical trial enrollment, with particular focus on lymphoid malignancies, CAR-T cell and bispecific antibody therapies.

oncology,hematology

The Challenges and Opportunities in Clinical Trial Diversity Mistrust in the healthcare system is a significant barrier to recruitment

Enhancing Diversity and Inclusion in Clinical Trials

Clinical Trial Access in Diverse Populations

Challenges and strategies for recruitment of minorities to clinical research and trials

Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives

Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Why diversity is needed at every level of clinical trials, from participants to leaders

Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel

On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.

A successful clinical trial ecosystem offers equal opportunities for all citizens

How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.

Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies

Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

Digital technologies used in clinical trial recruitment and enrollment including application to trial diversity and inclusion: A systematic review

Regulatory landscape with U.S. patient requirements and Clinical Trial Diversity expectations

Abstract A087: "Trust is built in teaspoons and it's lost in buckets": Clinical trial recruitment of Black individuals with lung cancer

Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators.

"First, Trust Needs to Develop": Hematologists' Perspectives on Factors Influencing Black Persons' Participation in Clinical Trials

Critical decisions: A mixed-methods study of decision-making among diverse gynecologic cancer patients considering therapeutic clinical trial enrollment

Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone

Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies